CNE Information

Target Audience

Oncology Nurses, including generalists, nurse navigators, advanced nursing providers (MSN, APN, and NP) who specialize in the care of patients with cancer; and nurses from other subspecialties who care for patients with cancer throughout their disease trajectory (surgical, radiation, palliative/hospice, and primary/medical subspecialty nurses).

Program Overview

The world is changing at an increasingly rapid pace. It has never been more important for nursing professionals to stay up-to-date on the changes and innovations in medicine. In addition to the rapid changes in clinical practice, there are challenges in the workforce including chronic staffing shortages, drug shortages, high patient-staff ratios, the persistent impact of COVID-19, a lack of resources for ongoing education as well as access and cost of treatment. All of which can affect patient care/outcomes, lead to moral distress, burnout, and ineffective staff collaboration.

The practice and importance of nursing continues to be elevated, highlighting the critical roles that nurses play in patient outcomes. Likewise, the day-to-day challenges and realities nurses face have been exposed, as every single day nurses tackle matters affecting health, education, environment, and economy.

The ONA Summit 2025 will deliver education based on the science of today, and on the well-established competencies of nursing roles, in an integrated manner that demonstrates the power of intra-professional collaboration, (generalists, advanced providers (MSN, APN, NP), and nurse navigators) unifies and strengthens not only the patient care delivered, but nursing as a profession. These foundations, along with outcomes data from the highly successful 2024 ONA Summit, will guide curriculum development for the 2025 conference. Knowledge and competence gaps previously identified will result in deeper dives into complex or high volume/high-risk topics; and newly identified therapeutic topics reflect 2024 learner-identified gaps in knowledge and competence.

Overall Learning Objectives

After participating in this CE activity, clinicians should be better able to:

1. Assess subjective and objective data, including preventive, pathophysiologic, and patient-specific data to develop clinical diagnoses for patients with cancer.

2. Plan evidence-based interventions to holistically address oncology patient care needs.

3. Implement practical, evidence-based, collaborative nursing care to patients with cancer, and their family/caregivers.

4. Evaluate practical strategies to optimize nursing management of the unique needs of patients with cancer.

Continuing Nursing Education

Provided by Haymarket Medical Education in association with Oncology Nurse Advisor and in collaboration with Fox Chase Cancer Center

Joint Accreditation

In support of improving patient care, Haymarket Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

This activity is awarded up to 12 contact hours (based on 60 minutes per contact hour), with 8.25 pharmacology hours assigned.

Nurse Practitioners

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and Haymarket Medical Education (HME). NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 12 contact hours (which includes 8.25 pharmacology hours).

Based on final content of all the presentations, Pharmacology hours will be assigned and ILNA categories be identified.

Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Haymarket Medical Education (HME) and NACE require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. HME and NACE mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities prior to the live program.

Planners

Nurse planners will have performed a review of the planned program content and will monitor the presentations to ensure there is no bias. Planning Committee members designing and selecting the content to be developed, have no disclosures.

Peer Review

Bernadette Makar, MSN, NP

Saint Peter’s University Hospital
Coordinator House Service Program
New Brunswick, NJ
Rutgers University
Clinical Adjunct
Newark, NJ

Ms. Maker has nothing to disclose.

Disclosure of Unlabeled Use

The presentations at the Summit meeting may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of HME, NACE, Fox Chase Cancer Center, or Oncology Nurse Advisor. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

This activity is being provided by HME. HME is providing ANCC contact hours for this program and maintains responsibility for adherence to Joint Accreditation criteria.

NACE is providing AANP contact hours and maintains responsibility for adherence to AANP criteria.

For more information about the accreditation of this program, please contact Sara Brykalski at Sara.Brykalski@haymarketmedical.com.

Instructions to Claim and Receive Credit

Please review these instructions on how to claim credit and keep them handy. In addition, these instructions are included within the handout section for each of the live presentations. Statements of credit will be awarded based on the participant's attendance and submission of the online activity evaluation form.

EVALUATION FORM ACCESS: You will receive an email on March 26^th with the subject line: Oncology Nurse Advisor Summit Evaluation, and you will be able to start the evaluation survey via this email.

THE EVALUATION FORM covers all the sessions presented and includes general questions that will help us plan for meetings. The survey must be filled out in its entirety to move you along in the process to claim credit.

At the end of the evaluation survey, click DONE to be directed back to NACE, the website you used to register and participate in the Summit. There, you’ll be able to complete the process to obtain your credits and certificate.

YOU MUST TAKE ACTION TO ATTEST TO YOUR ATTENDANCE AND CLAIM YOUR CREDIT. COMPLETING THE EVALUATION SURVEY IS NOT THE LAST STEP.

You will be able to attest to your time spent and choose a certificate and credit type. Nurse Practitioners should choose AANP credit; all others should choose ANCC credit.

When you complete the credit claim process, your certificate will be emailed to the address you used to register for the event. This email will come from NACE, the Accredited Provider’s meeting platform, which is the same platform that you used to register for the event.

Any questions issues on processing your evaluation form for credit, please email Christie.Kavanagh@haymarketmedical.com.

We ask that you complete and submit your evaluation as soon as possible and, in any case, no later than May 30, 2025.

Thank you for your participation!

Educational Support

Summit is currently being supported in part by educational grants from AbbVie, Inc., BeiGene USA, Inc.; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc. and Sumitomo Pharma America.